Bilirubin unbound: Déjà vu all over again?

Pediatrics

Volumn 117, Issue 2, 2006, Pages 523-525

  McDonagh, Antony F ^a   Maisels, M Jeffrey ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; PHENYLBUTAZONE; SULFONAMIDE; TOLBUTAMIDE; WARFARIN; SERUM ALBUMIN;

BILIRUBIN BLOOD LEVEL; DIABETES MELLITUS; DRUG POTENTIATION; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOPEROXIDASE STAINING; KERNICTERUS; NEWBORN JAUNDICE; NOTE; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN BINDING; BLOOD; BLOOD BRAIN BARRIER; BRAIN; METABOLISM; NEWBORN; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

BILIRUBIN; BLOOD-BRAIN BARRIER; BRAIN; HUMANS; INFANT, NEWBORN; JAUNDICE, NEONATAL; KERNICTERUS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN;

EID: 33644872733     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-2073     Document Type: Note

References (25)

1. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115-121
2. Rolan PE. Plasma protein binding displacement interactions: why are they still regarded as clinically important? Br J Clin Pharmacol. 1994;37:125-128
3. Sansom LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf. 1995;12:227-233
4. Silverman WA, Andersen DH, Blanc WA, Crozier DN. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics. 1956;18:614-615
5. Brodersen R. Aqueous solubility, albumin binding, and tissue distribution of bilirubin. In: Ostrow JD, ed. Bile Pigments and Jaundice. New York, NY: Marcel Dekker, Inc; 1986:157-181
6. Wennberg RP, Ahlfors CE, Bhutani VK, Johnson LH, Shapiro SM. Toward understanding kernicterus: a challenge to improve the management of jaundiced newborns. Pediatrics. 2006;117:474-485
7. Ip S, Chung M, Kulig J, et al. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics. 2004;114(1). Available at: www.pediatrics.org/cgi/content/full/114/1/e130
8. Bhutani VK, Johnson LH, Maisels JM, et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol. 2004;24:650-662
9. American Academy of Pediatrics, Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation [published correction appears in Pediatrics. 2004;114:1138]. Pediatrics. 2004;114:297-316
10. Maisels MJ. Phototherapy: traditional and nontraditional. J Perinatol. 2001;21(suppl 1):S93-S97; discussion S104-S107
11. Patra K, Storfer-Isser A, Siner B, Moore J, Hack M. Adverse events associated with neonatal exchange transfusion in the 1990s. J Pediatr. 2004;144:626-631
12. Seidman DS, Moise J, Ergaz Z, et al. A new blue light-emitting phototherapy device: a prospective randomized controlled study. J Pediatr. 2000;136:771-774
13. Kappas A. A method for interdicting the development of severe jaundice in newborns by inhibiting the production of bilirubin. Pediatrics. 2004;113:119-123
14. Oh W, Tyson JE, Fanaroff AA, et al. Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants. Pediatrics. 2003;112:773-779
15. Sugama S, Soeda A, Eto Y. Magnetic resonance imaging in three children with kernicterus. Pediatr Neurol. 2001;25:328-331
16. Govaert P, Lequin M, Swarte R, et al. Changes in globus pallidus with (pre)term kernicterus. Pediatrics. 2003;112:1256-1263
17. Brodersen R, Cashore WJ, Wennberg RP, Ahlfors CE, Rasmussen LF, Shusterman D. Kinetics of bilirubin oxidation with peroxidase, as applied to studies of bilirubin-albumin binding. Scand J Clin Lab Invest. 1979;39:143-150
18. Øie S, Levy G. Effect of sulfisoxazole on pharmacokinetics of free and plasma protein-bound bilirubin in experimental unconjugated hyperbilirubinemia. J Pharm Sci. 1979;68:6-9
19. Øie S, Levy G. Effect of salicylic acid on pharmacokinetics of free and plasma protein-bound bilirubin in experimental unconjugated hyperbilirubinemia. J Pharm Sci. 1979;68:1-6
20. Vreman HJ, Verter J, Oh W, et al. Interlaboratory variability of bilirubin measurements. Clin Chem. 1996;42:869-873
21. Ennever JF. Blue light, green light, white light, more light: treatment of neonatal jaundice. Clin Perinatol. 1990;17:467-481
22. Itoh S, Yamakawa T, Onishi S, Isobe K, Manabe M, Sasaki K. The effect of bilirubin photoisomers on unbound-bilirubin concentrations estimated by the peroxidase method. Biochem J. 1986;239:417-421
23. Blackmon LR, Fanaroff AA, Raju TN; National Institute of Child Health and Human Development. Research on prevention of bilirubin-induced brain injury and kernicterus: National Institute of Child Health and Human Development conference executive summary. 2003. Pediatrics. 2004;114:229-233
24. Cashore WJ, Oh W, Blumberg WE, Eisinger J, Lamola AA. Rapid fluorometric assay of bilirubin and bilirubin binding capacity in blood of jaundiced neonates: comparisons with other methods. Pediatrics. 1980;66:411-416
25. Ahlfors CE, Marshall DE, Wolcott DK, et al. Measurement of unbound bilirubin by the peroxidase test using Zone Fluidics. Clin Chem. 2005; In press. Abstract available at: www.sciencedirect.com/science/article/B6T57- 4H87GJR-4/2/ d795e139a99bf19acdb88353433adlc5